None listed
Conditions
Brief summary
This pilot study will determine the relationship between of pre-, during treatment and post-radiotherapy (+/- chemotherapy) MRI sequences (including DW and DCE-MRI) with respect to CNS tumour response and local intra-cranial control, post radiotherapy. and also determine the utility of MRI for assessing changes to the hippocampal region from CNS radiation therapy Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been newly diagnosed with primary or secondary brain cancer. Study details Participants will undergo normal MRI testing at baseline with an addition of 3 more times. During RT (Week 3 and 6) and then again 4 weeks post RT
Interventions
This study involves observing radiotherapy treatment response using novel MRI sequences as imaging biomarkers in participants undergoing standard radiotherapy and/or chemotherapy treatment.
Standard Treatment - DW, DCE, SWI and ASL MRI at radiotherapy simulation (Radiotherapy treatment planning to map out treatment delivery) (week 0)
Radiotherapy begins at Week 1
Extra test for pts on study
- DW, DCE, SWI and ASL MRI (weeks 3 and 6)
- at 4 weeks post RT - DW, DCE, SWI and ASL MRI
Abbreviations:
This study involves observing radiotherapy treatment response using novel MRI sequences as imaging biomarkers in participants undergoing standard radiotherapy and/or chemotherapy treatment. Standard Treatment - DW, DCE, SWI and ASL MRI at radiotherapy simulation (Radiotherapy treatment planning to map out treatment delivery) (week 0) Radiotherapy begins at Week 1 Extra test for pts on study - DW, DCE, SWI and ASL MRI (weeks 3 and 6) - at 4 weeks post RT - DW, DCE, SWI and ASL MRI Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling These scan are to gain anatomical and physiological information. The MRI images will require administration of an intravenous contrast agent. The MRI scan will take approximately 30-45 minutes and a contrast agent will be administered through a cannula during this examination. The MRIs will be undertaken by clinical MRI and radiotherapy staff with expertise required for clinical use of this imaging modality
Sponsors
Dr Eng-Siew Koh
Study design
Allocation
Non-randomised trial
Primary purpose
Diagnosis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
18 years or older Have the ability to give informed consent Histologically-proven primary or secondary brain cancer Plan to have radiotherapy treatment
Exclusion criteria
Contraindication to MRI studies Significant claustrophobia Pacemaker/implantable defibrillator Implanted metals eg. Intraocular clips Known allergic reaction to Gd-DTPA
Outcome results
None listed